Vedolizumab (anti-α4β7) Trough level
| Category | Immunology |
|---|---|
| Test background |
Vedolizumab (Entyvio©) is a humanised IgG1 antibody approved for use in Crohn’s disease and ulcerative colitis. Vedolizumab inhibits the action of the mucosal trafficking α4β7 integrin and prevents migration of inflammatory T cells to the gut. Response rates to vedolizumab are around 45% and early vedolizumab trough levels correlate with therapeutic outcomes in IBD. Dose escalation may induce or restore clinical response. Vedolizumab levels are measured in serum taken from patients just before an infusion (trough) using an indirect ELISA coated with α4β7 integrin. |
| Clinical Indications |
For the monitoring of drug trough levels in IBD patients treated with Vedolizumab. |
| Reference range | Negative (for patients never treated with vedolizumab) Target trough levels for vedolizumab differ based on sampling time point (induction vs maintenance) and the target therapeutic outcome (clinical response vs endoscopic remission). Nassar IO, et al. Frontline Gastroenterol. 2022 Jan 24;13(5):430-435. doi: 10.1136/flgastro-2021-102032. |
| Sample & container required | Serum (rust top) vacutainer |
| Sample volume | 0.5ml |
| Sample collection | Samples should be taken just before the next infusion of drug (trough) |
| Turnaround time | 4 weeks |